As part of the agreement, Abingdon will provide clinical and regulatory services for Stason’s pipeline of potential drug candidates and devices in the areas of cancer and inflammation.
Richard Lebovitz, CEO of Abingdon, said: “We are extremely happy to have formalized our relationship with Stason, and believe that this represents a synergistic opportunity for both our companies to leverage our respective core competencies in drug development and manufacturing.”